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Metabolism, Gliomas, and IDH1
Jan Smeitink, M.D., Ph.D.
Since the first description of a patient with an 
inborn error of metabolism was provided by Sir 
Archibald Edward Garrod more than 100 years 
ago, the study of rare disorders has received in-
creasing attention. What started with the descrip-
tion of a single patient has evolved into a medi-
cal discipline — the study of metabolic disease 
— that pertains to common conditions, such as 
the process of aging, and common diseases, such 
as diabetes and cancer. On this note, Dang and 
coworkers1 recently elucidated the effect of a mu-
tant gene encoding cytosolic isocitrate dehydro-
genase 1 (IDH1) on tumorigenesis, taking advan-
tage of studies of persons with metabolic disease 
who excrete excessive amounts of 2-hydroxyglu-
taric acid in urine. The investigators found that 
a mutation observed in the IDH1 gene, which oc-
curs in the majority of grade II and grade III 
gliomas and secondary glioblastomas, effects both 
a gain of function and a loss of function.
The isocitrate dehydrogenases catalyze the oxi-
dative decarboxylation of isocitrate to alpha-keto-
glutarate, generating NADPH from NADP+. Sev-
eral isocitrate dehydrogenases exist, each with a 
different cellular localization. IDH1, the focus of 
the work of Dang and colleagues, is localized in 
the cytoplasm and the peroxisomes.
Their work showed that the mutant IDH1 ac-
quires the ability to convert alpha-ketoglutarate 
to 2-hydroxyglutarate (Fig. 1),1 which is known to 
accumulate in the inborn errors of metabolism 
that occur in the disorder 2-hydroxyglutaric aci-
duria.2,3 The accumulating metabolite, 2-hydroxy-
glutarate, exists in the form of two enantiomers, 
l-2-hydroxyglutarate and d-2-hydroxyglutarate 
(each the mirror image of the other), both of 
which accumulate whenever the relevant convert-
ing enzyme is defective. Dang and colleagues 
reported several findings, showing that cells ex-
pressing mutant IDH1 have elevated concentrations 
of 2-hydroxyglutarate, that the crystal structure 
of the mutant IDH1 enzyme reveals a distinct 
and novel active site, that the mutant consequent-
ly converts α-ketoglutarate to 2-hydroxyglutarate 
and has diminished ability to convert isocitrate 
to α-ketoglutarate, that levels of 2-hydroxyglu-
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Figure 1. When Loss Means Gain.
When the gene encoding cytosolic isocitrate dehydrogenase (IDH1) is normal, the enzyme shown in green catalyzes 
the conversion of d-isocitrate to α-ketoglutarate (left panel). A specific mutation in the IDH1 gene is associated with 
susceptibility to glioma with good prognosis. This mutation changes the structure of the enzyme shown in orange, 
which diminishes its ability to convert d-isocitrate to α-ketoglutarate and provides it with a newly acquired ability to 
convert α-ketoglutarate to d-2-hydroxyglutarate.
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tarate are elevated in samples of human glioma, 
and that the accumulating 2-hydroxyglutarate is 
the d-2 enantiomer.
The finding that cancer-associated IDH1 mu-
tations result in the accumulation of 2-hydroxy-
glutarate provides an explanation for the patho-
physiology of these particular tumors. That said, 
these findings would seem to be at odds with 
findings on the different forms of inborn errors 
of metabolism in which 2-hydroxyglutarate is 
produced — l-2-hydroxyglutaric aciduria and d-2-
hydroxyglutaric aciduria. Specifically, l-2-hydroxy-
glutaric aciduria is associated with brain tumors 
and d-2-hydroxyglutaric aciduria is not (Jakobs C: 
personal communication).4,5 Thus, the conclusion 
that d-2-hydroxyglutarate is the “causative” onco-
metabolite in gliomas and secondary glioblasto-
mas warrants further investigation. Because IDH1 
mutations occur predominantly in younger pa-
tients and are associated with a better prognosis 
than is the case with tumors that do not carry the 
IDH1 mutation, d-2-hydroxyglutarate may become 
a biomarker, serving diagnostic, prognostic, and 
therapeutic purposes. One wonders whether d-2-
hydroxyglutarate is also increased in patients with 
mutations in the IDH2 gene, which encodes a mi-
tochondrial isocitrate dehydrogenase.
The research by Dang and colleagues illustrates 
how the study of inborn errors of metabolism 
facilitates an understanding of the pathophysiol-
ogy of more common disorders. Archibald Gar-
rod would be impressed.
Disclosure forms provided by the author are available with the 
full text of this article at NEJM.org.
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clinical trial registration
The Journal requires investigators to register their clinical trials  
in a public trials registry. The members of the International Committee  
of Medical Journal Editors (ICMJE) will consider most clinical trials for publication 
only if they have been registered (see N Engl J Med 2004;351:1250-1).  
Current information on requirements and appropriate registries  
is available at www.icmje.org/faq.pdf.
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